Molecular typing is based on molecular genetic screening and isn't yet routinely offered. Molecular subtypes and immunohistochemical surrogate markers of your tumors (HR, HER2, triple unfavorable) correlate in about 70%. The differentiation of luminal A and B subtypes by HR position and prol